Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma

Tao, Haisu; Zhang, Yuxin; Li, Jiang; Liu, Junjie; Yuan, Tong; Wang, Wenqiang; Liang, Huifang; Zhang, Erlei; Huang, Zhiyong

doi:10.1016/j.omto.2022.12.005

Cited by 17 publications

(16 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In respiratory system tumors, BBOX1-AS1 exhibits a significant positive correlation with larger tumor size, lymph node metastasis, and advanced Tumour-Node-Metastasis (TNM) stage in NSCLC [ 39 , 40 ]. Similarly, in digestive system tumors [ 41 , 43 , 44 , 46 – 48 ], BBOX1-AS1 shows a significant positive association with larger tumor size, lymph node metastasis, or advanced TNM stage. Notably, high BBOX1-AS1 expression is positively correlated with lymph node metastasis in esophageal carcinoma [ 41 , 44 ] and gastric cancer [ 48 ].…”

Section: Bbox1-as1 Expression and Its Associations With Clinical Feat...mentioning

confidence: 95%

“…Notably, high BBOX1-AS1 expression is positively correlated with lymph node metastasis in esophageal carcinoma [ 41 , 44 ] and gastric cancer [ 48 ]. Elevated BBOX1-AS1 expression is linked to positive vascular invasion, higher tumor grade, and advanced clinical stage in hepatocellular carcinoma [ 46 , 47 ]. In the context of reproductive tumors, high expression of BBOX1-AS1 indicates more aggressive phenotypes [ 53 ], including larger tumor size, poor differentiation, distant metastasis, and higher FIGO stage in cervical cancer.…”

Section: Bbox1-as1 Expression and Its Associations With Clinical Feat...mentioning

confidence: 99%

“…Several studies have reported a significant relationship between aberrant BBOX1-AS1 expression and cancer patient prognosis. As indicated in Table 1 , high expression of BBOX1-AS1 was found to predict poor overall survival in four types of cancers: non-small cell lung cancer [ 39 , 40 ], esophageal squamous cell carcinoma [ 41 , 43 , 44 ], hepatocellular carcinoma [ 46 , 47 ], and cervical cancer [ 53 ], as well as inferior disease-free survival in hepatocellular carcinoma [ 47 ]. Additionally, several prognostic models that incorporate BBOX1-AS1 have been developed.…”

Section: Bbox1-as1 As a Diagnostic And Prognostic Marker In Cancersmentioning

confidence: 99%

“…BBOX1-AS1 demonstrates upregulation in a wide range of human tumors (Fig. 1 ), including pituitary adenoma (PA) [ 34 ], oral squamous cell carcinoma (OSCC) [ 35 ], nasopharyngeal carcinoma (NPC) [ 36 , 37 ], non-small cell lung cancer (NSCLC) [ 38 – 40 ], esophageal carcinoma (EC) [ 41 – 45 ], hepatocellular carcinoma (HCC) [ 46 , 47 ], gastric cancer (GC) [ 48 ], colorectal cancer (CRC) [ 49 , 50 ], ovarian cancer (OC) [ 51 ], and cervical cancer (CC) [ 52 , 53 ]. High expression levels of BBOX1-AS1 in tumor patients have been linked to adverse clinicopathological features and poor prognosis, including lymph node metastasis, tumor size, clinical stage, overall survival (OS), and disease-free survival (DFS).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression

Hu,

Liu,

Zhou

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

Gamma-butyrobetaine hydroxylase 1 antisense RNA 1 (BBOX1-AS1), located on human chromosome 11 p14, emerges as a critical player in tumorigenesis with diverse oncogenic effects. Aberrant expression of BBOX1-AS1 intricately regulates various cellular processes, including cell growth, epithelial–mesenchymal transition, migration, invasion, metastasis, cell death, and stemness. Notably, the expression of BBOX1-AS1 was significantly correlated with clinical-pathological characteristics and tumor prognoses, and it could also be used for the diagnosis of lung and esophageal cancers. Through its involvement in the ceRNA network, BBOX1-AS1 competitively binds to eight miRNAs in ten different cancer types. Additionally, BBOX1-AS1 can directly modulate downstream protein-coding genes or act as an mRNA stabilizer. The implications of BBOX1-AS1 extend to critical signaling pathways, including Hedgehog, Wnt/β-catenin, and MELK/FAK pathways. Moreover, it influences drug resistance in hepatocellular carcinoma. The present study provides a systematic review of the clinical significance of BBOX1-AS1’s aberrant expression in diverse tumor types. It sheds light on the intricate molecular mechanisms through which BBOX1-AS1 influences cancer initiation and progression and outlines potential avenues for future research in this field.

show abstract

Section: Bbox1-as1 Expression and Its Associations With Clinical Feat...mentioning

confidence: 95%

Section: Bbox1-as1 Expression and Its Associations With Clinical Feat...mentioning

confidence: 99%

Section: Bbox1-as1 As a Diagnostic And Prognostic Marker In Cancersmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression

Hu,

Liu,

Zhou

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…PHF8 is a histone lysine demethylase that functions as a transcriptional activator. lncRNA BBOX1-AS1 is upregulated in HCC patients, and it upregulated PHF8 by sponging miR-361-3p, which contributed to HCC progression, autophagy, and sorafenib resistance [ 201 ]. The mechanism by which PHF8 regulates these phenotypes remains to be determined.…”

Section: Lncrnas Modulating Current Hcc Treatmentmentioning

confidence: 99%

HCC-Related lncRNAs: Roles and Mechanisms

Shah,

Sarkar

2024

IJMS

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) presents a significant global health threat, particularly in regions endemic to hepatitis B and C viruses, and because of the ongoing pandemic of obesity causing metabolic-dysfunction-related fatty liver disease (MAFLD), a precursor to HCC. The molecular intricacies of HCC, genetic and epigenetic alterations, and dysregulated signaling pathways facilitate personalized treatment strategies based on molecular profiling. Epigenetic regulation, encompassing DNA methyltion, histone modifications, and noncoding RNAs, functions as a critical layer influencing HCC development. Long noncoding RNAs (lncRNAs) are spotlighted for their diverse roles in gene regulation and their potential as diagnostic and therapeutic tools in cancer. In this review, we explore the pivotal role of lncRNAs in HCC, including MAFLD and viral hepatitis, the most prevalent risk factors for hepatocarcinogenesis. The dysregulation of lncRNAs is implicated in HCC progression by modulating chromatin regulation and transcription, sponging miRNAs, and influencing structural functions. The ongoing studies on lncRNAs contribute to a deeper comprehension of HCC pathogenesis and offer promising routes for precision medicine, highlighting the utility of lncRNAs as early biomarkers, prognostic indicators, and therapeutic targets.

show abstract

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)

Zhang,

Guo,

Yuan

et al. 2024

Global Challenges

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer, characterized by a dismal prognosis. Therapeutic options for advanced HCC remain sparse, with efficacy significantly hampered by the emergence of drug resistance. In parallel with research into novel pharmacological agents, advances in drug delivery systems represent a promising avenue for overcoming resistance. Lipid nanoparticles (LNPs) have demonstrated considerable efficacy in the delivery of nucleic acid‐based therapeutics and hold potential for broader applications in drug delivery. This review describes the development of LNPs tailored for HCC treatment and consolidates recent investigations using LNPs to target HCC.

show abstract

Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma

Cited by 17 publications

References 38 publications

A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression

A review on the role of gamma-butyrobetaine hydroxylase 1 antisense RNA 1 in the carcinogenesis and tumor progression

HCC-Related lncRNAs: Roles and Mechanisms

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)

Contact Info

Product

Resources

About